This Article contains errors in Figs. 1 and 8 that were introduced during the production process. The compound on the lower right side of Fig. 1 is labelled incorrectly and should be labelled ‘SC83288’. The correct version of Fig. 1 appears below as Fig. 1. In Fig. 8c, ‘SC83458 selected’ should read ‘SC81458 selected’ and in Fig. 8d ‘SC81758’ should read ‘SC81458’. The correct version of Fig. 8 appears below as Fig. 2.
Additional information
The online version of the original article can be found at 10.1038/ncomms14193
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Pegoraro, S., Duffey, M., Otto, T. et al. Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun 8, 15273 (2017). https://doi.org/10.1038/ncomms15273
Published:
DOI: https://doi.org/10.1038/ncomms15273
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
